Truist Securities Reiterates Buy Rating on Allogene (ALLO)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Allogene (ALLO) PT Lowered to $7 at B.Riley
May 14, 2024 7:33 AM EDT(Updated - May 14, 2024 7:34 AM EDT)
B.Riley analyst Kalpit Patel lowered the price target on Allogene (NASDAQ: ALLO) to $7.00 (from $10.00) while maintaining a Buy rating.
The analyst commented: "On Monday (5/13), Allogene Therapeutics reported 1Q24 earnings and provided a corporate update.... More
Allogene (ALLO) PT Raised to $4.60 at Stifel
May 14, 2024 3:05 AM EDTStifel analyst Benjamin Burnett raised the price target on Allogene (NASDAQ: ALLO) to $4.60 (from $4.40) while maintaining a Hold rating.... More
Allogene Therapeutics (ALLO) Announces Pricing of $110 million Offering of Common Stock
May 13, 2024 4:48 PM EDTAllogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced the pricing of an underwritten offering of 37,931,035 shares of its common stock at a price of $2.90 per share.... More
Allogene Therapeutics, Inc. (ALLO) Tops Q1 EPS by 3c
May 13, 2024 4:13 PM EDTAllogene Therapeutics, Inc. (NASDAQ: ALLO) reported Q1 EPS of ($0.38), $0.03 better than the analyst estimate of ($0.41).
For earnings history and earnings-related data on Allogene Therapeutics, Inc. (ALLO) click here.
... More